The SERODUS Study

 FlashGM

This Study is investigating the impact of a novel oral medication Ser150 in people with Type 2 diabetes with early kidney disease.

GET INVOLVED

This Study is investigating the impact of a novel oral medication
Ser150 in people with Type 2 diabetes with early kidney disease

The FlashGM Study

We are looking to engage people who have had Type 2 diabetes for at least 3 years and who are on a stable treatment regime but showing protein in their urine.

They will have an HbA1C of less than 10%

This trial runs for 16 weeks and there will be 8 site visits. Two of these visits are long days (approx. 7 hours) and will require the patient to have a cannula inserted in a vein for frequent blood testing. The other 6 site visits will require a blood test. An ECG (heart-tracing) will be done twice during the study.

Become a participant!

Meet Kim Henshaw who is a participant in type 1 diabetes technology research at the DTRG. Watch Kim explain what it means to her to be a participant in this important area of research.

Get involved

Please contact the Research Group Leader to discuss your options.